Research
Hormonal
Semaglutide has a favorable safety profile across diverse patient populations and treatment durations.
Clinicians can consider semaglutide as a safe option for managing type 2 diabetes and obesity.
StrongSupportsmedium confidence
Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations.
Why this rating
Based on the meta-analysis of 23 studies with a large sample size.
Source
Evaluating the safety profile of semaglutide: an updated meta-analysis
Frederick Berro Rivera et al. · Current Medical Research and Opinion · 2024
DOI 10.1080/03007995.2024.2383731
Meta-analysisCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →